C J Majoor1, M M S Sneeboer1, A de Kievit1, J C M Meijers2,3, T van der Poll4, R Lutter1,5, E H Bel1, P W Kamphuisen6. 1. Department of Respiratory Medicine, Academic Medical Center, Amsterdam, the Netherlands. 2. Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. 3. Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands. 4. Center of Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, the Netherlands. 5. Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands. 6. Department of Vascular Medicine, University Medical Center Groningen, Groningen, the Netherlands.
Abstract
BACKGROUND:Corticosteroids have been associated with an increased risk of venous thromboembolism in patients treated for inflammatory diseases. It is unclear whether the thrombotic risk is induced by the inflammation of the underlying inflammatory diseases or whether corticosteroids are prothrombotic as well. Considering the widespread use of corticosteroids in clinical practise, it is critical to know whether corticosteroids enhance coagulation. OBJECTIVE: To investigate whether a 10-day prednisolone burst therapy activates hemostasis in healthy individuals. METHODS:Healthy subjects received either 0.5 mg kg(-1) day(-1) of oral prednisolone or placebo. Venous blood was collected at baseline, day 1 and day 10 and tested for thrombin-antithrombin complexes (TATc), D-dimer, plasmin-alpha2-antiplasmin complexes (PAPc), plasminogen-activator inhibitor type-1 (PAI-1), von Willebrand factor (VWF) and thrombin generation (peak thrombin, velocity index and endogenous thrombin potential [ETP]). RESULTS: Fifteen subjects received prednisolone and 16 placebo (median age 29 vs. 22 years, female subjects 33% vs. 56%, respectively). Peak thrombin and velocity index were higher in the placebo group at baseline. After 10 days of treatment, peak thrombin, velocity index, PAI-1 and VWF increased in the oral prednisolone group as compared with the placebo group (15.8 [SD 16.3] vs. -0.1 [SD 16.1], 41.2 [SD 41.3] vs. -2.3 [SD 42.7], 18.0 [IQR 8.0-37.0] vs. 0.5 [IQR -18.5-13.0], 4.0 [IQR -1.0-12.0] vs. 0.0 [IQR -2.5-1.5], respectively). No changes were observed for TATc, ETP, PAPc and D-dimer. CONCLUSIONS:Oral prednisolone induces a procoagulant state in healthy subjects, suggesting that corticosteroid treatment may increase the thromboembolic risk in patients with inflammatory diseases.
RCT Entities:
BACKGROUND: Corticosteroids have been associated with an increased risk of venous thromboembolism in patients treated for inflammatory diseases. It is unclear whether the thrombotic risk is induced by the inflammation of the underlying inflammatory diseases or whether corticosteroids are prothrombotic as well. Considering the widespread use of corticosteroids in clinical practise, it is critical to know whether corticosteroids enhance coagulation. OBJECTIVE: To investigate whether a 10-day prednisolone burst therapy activates hemostasis in healthy individuals. METHODS: Healthy subjects received either 0.5 mg kg(-1) day(-1) of oral prednisolone or placebo. Venous blood was collected at baseline, day 1 and day 10 and tested for thrombin-antithrombin complexes (TATc), D-dimer, plasmin-alpha2-antiplasmin complexes (PAPc), plasminogen-activator inhibitor type-1 (PAI-1), von Willebrand factor (VWF) and thrombin generation (peak thrombin, velocity index and endogenous thrombin potential [ETP]). RESULTS: Fifteen subjects received prednisolone and 16 placebo (median age 29 vs. 22 years, female subjects 33% vs. 56%, respectively). Peak thrombin and velocity index were higher in the placebo group at baseline. After 10 days of treatment, peak thrombin, velocity index, PAI-1 and VWF increased in the oral prednisolone group as compared with the placebo group (15.8 [SD 16.3] vs. -0.1 [SD 16.1], 41.2 [SD 41.3] vs. -2.3 [SD 42.7], 18.0 [IQR 8.0-37.0] vs. 0.5 [IQR -18.5-13.0], 4.0 [IQR -1.0-12.0] vs. 0.0 [IQR -2.5-1.5], respectively). No changes were observed for TATc, ETP, PAPc and D-dimer. CONCLUSIONS: Oral prednisolone induces a procoagulant state in healthy subjects, suggesting that corticosteroid treatment may increase the thromboembolic risk in patients with inflammatory diseases.
Authors: David Alexander Christian Messerer; Holger Gaessler; Andrea Hoffmann; Michael Gröger; Kathrin Benz; Aileen Huhn; Felix Hezel; Enrico Calzia; Peter Radermacher; Thomas Datzmann Journal: Front Immunol Date: 2022-06-16 Impact factor: 8.786
Authors: J Bartko; C Schoergenhofer; M Schwameis; N Buchtele; J Wojta; G Schabbauer; L Stiebellehner; B Jilma Journal: J Thromb Haemost Date: 2016-10-24 Impact factor: 5.824
Authors: Amanda P Waller; Shipra Agrawal; Katelyn J Wolfgang; Jiro Kino; Melinda A Chanley; William E Smoyer; Bryce A Kerlin Journal: Physiol Rep Date: 2020-08